Recent years have seen biotechnology having an increasing impact on a variety of scientific spheres and disciplines. Lindsay Rosenwald's Paramount Group of Companies has been operating within biotechnology, research, and life science for over two decades. Over this time, Paramount supported, developed, and invested in over 40 research and science companies (20 of them over the last 3 years alone), which has established the Paramount Group of Companies as a global leader in biotechnology.
The Portfolio Companies can currently claim over 40 products that are advancing through clinical trials. Paramount has also shown a strong history on issues pertaining to science, industry, health and safety concerns in biotech and pharmaceuticals.
Paramount began when Dr. Lindsay Rosenwald founded Paramount Biosciences, LLC, which focused on the licensing of cutting-edge therapies and other medicine-related technologies. Paramount Biosciences is also involved in companies' incubation, governance, and business development. It immesurably supports corporate infrastructure utilizing its expertise in licensing, development, clinical operations, and regulations. Paramount BioCapital, Inc. is a FINRA registered broker-dealer, and is primarily focused on raising capital for Paramount's Portfolio Companies.
The executive leadership team at Paramount Biosciences has an extensive background in biotech, pharmaceutics, and financial operations.
Lindsay Rosenwald, M.D. is the Chairman and Chief Executive Officer, and Founder of Paramount Biosciences. With over two decades' experience in the development, financing, and investment in biotech and life science firms, Dr. Lindsay Rosenwald has made a remarkable contribution to today's biotechnology field. Lindsay Rosenwald also established a nonprofit charity, The Rosenwald Foundation Inc., which focuses on educational philanthropic research.
J. Jay Lobell, J.D. is the President and Chief Operating Officer. He came to Paramount after serving as a partner at law firm Covington & Burling. This background gave him vast experience in providing business, legal, and regulatory advice to financial institutions, corporations, and individuals.
Russell Ellison, M.D. serves as the Executive Vice President. Dr. Ellison has almost three decades' worth of experience in senior management pharmaceuticals, specifically in commercialization and drug research and development. Formerly, he served as VP of Clinical Development at Fibrogen, Inc., as well as the US Vice President of Medical Affairs and Chief Medical Officer at Sanofi-Synthelabo, USA. This extensive background proves his ability to successfully manage complex financial and corporate operations.
No comments:
Post a Comment